Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Ascendis Pharma A/S - Ordinary Share (ASND)
Last ascendis pharma a/s - ordinary share earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: GlobeNewswire
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “notes”) (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for redemption on May 6, 2026 (the “Redemption Date”). Ascendis’ redemption right in respect of the notes arises pursuant to Section 4.03(B) of the indenture (the “Indenture”), dated as of March 29, 2022, between Ascendis and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as a result of the last reported sale price per ordinary share having exceeded 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on, and including, April 21, 2026. Redemption ProcessThe redemption price will be payable on the Redemption Date in cash and equal to 100% of the principal amount of the notes ou
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - Ordinary Share news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqGlobeNewswire
- Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.MarketBeat
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.MarketBeat
- Ascendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire
- New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with AchondroplasiaGlobeNewswire
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 4/21/26 - Form 6-K
- 4/21/26 - Form 6-K
- 4/20/26 - Form 8-A12B/A
- ASND's page on the SEC website